Table 3.
Univariable analysis for progression-free and overall survival of 227 patients treated with cytoreductive surgery combined with perioperative chemotherapy for synchronous peritoneal metastases (stratified by center)
| Variable | Progression-free survival | Overall survival | ||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Age | 0.99 (0.98–1.01) | 0.184 | 0.98 (0.96–0.99) | 0.025 |
| Sex | ||||
| Female | 1 | 1 | ||
| Male | 1.17 (0.85–1.59) | 0.332 | 1.00 (0.67–1.50) | 0.985 |
| Body mass index | 1.01 (0.98–1.04) | 0.602 | 0.99 (0.95–1.03) | 0.550 |
| ASA | ||||
| 1 | 1.00 | 1.00 | ||
| 2 | 1.10 (0.76–1.60) | 0.597 | 1.02 (0.65–1.61) | 0.935 |
| 3/4 | 0.68 (0.33–1.37) | 0.280 | 0.63 (0.22–1.81) | 0.368 |
| Number of CRSs | ||||
| 1 | 1.00 | 1.00 | ||
| >1 | 1.28 (0.80–2.06) | 0.303 | 1.30 (0.73–2.32) | 0.369 |
| Period | ||||
| 2007–2015 | 1.00 | 1.00 | ||
| 2016–2020 | 0.74 (0.54–1.01) | 0.060 | 0.78 (0.49–1.22) | 0.275 |
| Primary tumor location | ||||
| Right colon | 1.00 | 1.00 | ||
|
Left colon T. colon Rectum |
0.82 (0.60–1.13) 0.56 (0.20–1.53) 0.72 (0.17–2.94) |
0.232 0.257 0.644 |
0.72 (0.48–1.09) 0.60 (0.15–2.49) 1.22 (0.29–5.09) |
0.122 0.485 0.783 |
| Primary T stage | ||||
| <4 | 1.00 | 1.00 | ||
| ≥4 | 1.30 (0.87–1.93) | 0.198 | 1.57 (0.92–2.68) | 0.095 |
| Primary N stage | ||||
| N0 | 1.00 | 1.00 | ||
| N1 | 1.38 (0.88–2.17) | 0.159 | 1.25 (0.66–2.36) | 0.497 |
| N2 | 1.94 (1.21–3.11) | 0.006 | 1.93 (1.01–3.70) | 0.048 |
| Number of neoadjuvant CT lines | ||||
| 1 | 1.00 | 1.00 | ||
| >1 | 1.32 (0.78–2.23) | 0.300 | 1.24 (0.59–2.57) | 0.573 |
| Neoadjuvant CT regimen | ||||
| Monotherapy/doublet | 1.00 | 1.00 | ||
| Triplet/quadruplet | 1.28 (0.93–1.76) | 0.127 | 1.37 (0.90–2.07) | 0.143 |
| Neoadjuvant biologic agent | ||||
| No | 1.00 | 1.00 | ||
| Yes | 1.69 (1.25–2.30) | 0.001 | 1.63 (1.10–2.43) | 0.016 |
| Neoadjuvant bevacizumab agent | ||||
| No | 1.00 | 1.00 | ||
| Yes | 1.77 (1.27–2.47) | 0.001 | 1.58 (1.04–2.40) | 0.030 |
| No. of neoadjuvant CT cycles | 1.02 (0.98–1.07) | 0.289 | 1.01 (0.95–1.08) | 0.649 |
| Preoperative interval without CT | ||||
| >42 days | 1.00 | 1.00 | ||
| ≤42 days | 0.70 (0.49–0.99) | 0.042 | 0.44 (0.29–0.68) | < 0.001 |
| Peritoneal Cancer Index | 1.03 (1.01–1.05) | 0.001 | 1.05 (1.03–1.08) | < 0.0001 |
| Completeness of cytoreductive surgery | ||||
| CC0 | 1.00 | 1.00 | ||
| CC1 | 1.01 (0.49–2.06) | 0.984 | 1.40 (0.61–3.23) | 0.428 |
| HIPEC | ||||
| No | 1.00 | 1 | ||
| Yes | 0.61 (0.40–0.92) | 0.018 | 0.75 (0.44–1.27) | 0.285 |
| KRAS status | ||||
| Wild-type | 1.00 | 1.00 | ||
| Mutated | 1.06 (0.75–1.50) | 0.729 | 0.78 (0.50–1.24) | 0.294 |
| Postoperative morbidity at 90 days (grade III–IV) | ||||
| No | 1.00 | 1.00 | ||
| Yes | 0.94 (0.70–1.31) | 0.694 | 1.21 (0.79–1.87) | 0.376 |
| Number of days of hospitalization | 1.01 (0.99–1.03) | 0.103 | 1.02 (1.01–1.04) | 0.016 |
| Adjuvant CT protocol | ||||
| Mono/doublet | 1.00 | 1.00 | ||
| Triplet/quadruplet | 1.19 (0.77–1.84) | 0.438 | 1.19 (0.77–1.84) | 0.438 |
| Adjuvant biologic agent | ||||
| No | 1.00 | 1.00 | ||
| Yes | 1.38 (0.97–1.95) | 0.074 | 1.13 (0.72–1.78) | 0.588 |
| Number of adjuvant CT cycles | 0.91 (0.84–0.98) | 0.017 | 0.95 (0.86–1.05) | 0.350 |
| Total number of perioperative CT cycles | 0.98 (0.93–1.04) | 0.516 | 0.99 (0.92–1.06) | 0.701 |
Significant results are in bold
ASA American society of anesthesiologists, CRS cytoreductive surgery, T colon transverse colon, CT chemotherapy, HIPEC hyperthermic intraperitoneal chemotherapy